Eli LillyLLY
LLY
About: Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.
Employees: 43,000
0
Funds holding %
of 7,139 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
114% more first-time investments, than exits
New positions opened: 413 | Existing positions closed: 193
1% more funds holding
Funds holding: 3,600 [Q3] → 3,646 (+46) [Q4]
4% more repeat investments, than reductions
Existing positions increased: 1,457 | Existing positions reduced: 1,406
9% less call options, than puts
Call options by funds: $9.26B | Put options by funds: $10.1B
2.08% less ownership
Funds ownership: 83.89% [Q3] → 81.81% (-2.08%) [Q4]
13% less capital invested
Capital invested by funds: $694B [Q3] → $602B (-$91.3B) [Q4]
32% less funds holding in top 10
Funds holding in top 10: 462 [Q3] → 315 (-147) [Q4]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$970
11%
upside
Avg. target
$1,049
20%
upside
High target
$1,190
36%
upside
4 analyst ratings
4 positive
100%
0 neutral
0%
0 negative
0%
Truist Securities Srikripa Devarakonda 34% 1-year accuracy 12 / 35 met price target | 19%upside $1,038 | Buy Maintained | 3 Feb 2025 |
Wells Fargo Mohit Bansal 44% 1-year accuracy 11 / 25 met price target | 11%upside $970 | Overweight Maintained | 28 Jan 2025 |
Citigroup Peter Verdult 33% 1-year accuracy 1 / 3 met price target | 36%upside $1,190 | Buy Maintained | 28 Jan 2025 |
B of A Securities Tim Anderson 56% 1-year accuracy 5 / 9 met price target | 14%upside $997 | Buy Reinstated | 10 Dec 2024 |
Financial journalist opinion
Based on 94 articles about LLY published over the past 30 days
Positive
The Motley Fool
2 hours ago
3 Magnificent Growth Stocks to Buy Right Now
In a sense, every investor is a growth investor. Even those who are primarily seeking income enjoy when the stocks they buy increase in value.
Positive
24/7 Wall Street
19 hours ago
This Growth Stock Surged 63% in 2024. Here's Why 2025 Could Bring An Even Bigger Gain.
The big pharma sector is one that's generally fallen out of favor for many investors over the past few decades, as large healthcare companies have seen slower growth and consolidation hasn't generally provided the kind of upside investors had grown accustomed to over the latter half of the past century.
Positive
Zacks Investment Research
22 hours ago
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Positive
Finbold
1 day ago
Grok 3 makes ideal stock portfolio for 2025
Artificial intelligence (AI) platforms have been enjoying the spotlight since the original release of ChatGPT in late 2022 and have started gaining increasing traction among investors for apparently outperforming a significant portion of professional managers.
Positive
Reuters
1 day ago
Eli Lilly bets big on weight-loss pill with $550 million inventory stockpile
Eli Lilly is betting big on its experimental oral weight-loss drug even before reporting data from its late-stage trial by recording nearly $550 million in "pre-launch inventory" in its financial statements, a filing showed on Wednesday.
Negative
Zacks Investment Research
1 day ago
Don't Overlook Lilly (LLY) International Revenue Trends While Assessing the Stock
Review Lilly's (LLY) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
Positive
CNBC Television
1 day ago
Lilly's Chief Scientific Officer: 'We have an obligation to go after big problems'
Eli Lilly's Chief Scientific Officer Dan Skovronsky says the company wants to take big swings in Alzheimer's, ALS, chronic pain and other difficult diseases after its success in obesity.
Positive
CNBC Television
1 day ago
Lilly's Chief Scientific Officer has big plans for the next generation of weight loss drugs
Eli Lilly's Chief Scientific Officer Dan Skovronsky says the company wants to take big swings in Alzheimer's, ALS, chronic pain and other difficult diseases after its success in obesity.
Positive
CNBC
1 day ago
Eli Lilly aims to invest in 'big problems hiding in plain sight' using obesity windfall
Eli Lilly's GLP-1 drugs Mounjaro and Zepbound are transforming the company. Lilly now has an obligation to take on other challenging diseases like Alzheimer's, ALS and chronic pain, said the the company's Chief Scientific Officer Dan Skovronsky.
Positive
CNBC
1 day ago
From pills to new uses, here's what Eli Lilly's top scientist sees as the future of weight loss drugs
Eli Lilly Chief Scientific Officer Dan Skovronsky said newer obesity medicines need to deliver more than just weight loss to compete with Zepbound and Wegovy. The development of pills and more potent drugs are two areas where Lilly is focusing.
Charts implemented using Lightweight Charts™